卢沃美提尼布:首次获得批准
1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|August 2, 2025
概括
作为MEK1/2抑制剂的luvometinib现在已在中国批准用于治疗罕见疾病. 它用于治疗成人朗格汉斯细胞囊细胞瘤和儿科神经纤维素瘤1型与plexiform神经纤维瘤.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 卢沃美替尼布是一种口服MEK1/2抑制剂,向MAPK通路激活.
- 罕见的恶性瘤和疾病通常涉及异常的MAPK信号传递.
- 福森制药公司开发了luvometinib,以满足罕见疾病中未满足的需求.
研究的目的:
- 总结一下luvometinib的发展里程碑.
- 为了突出其针对特定罕见疾病的首次批准.
主要方法:
- 审查卢沃美替尼布的开发过程.
- 对临床数据的分析,从而获得监管部门的批准.
主要成果:
- 卢沃美替尼布于2025年5月在中国获得批准.
- 适应症包括成人LCH/囊性瘤和患有症状PN的儿科NF1.
- 该批准涵盖年龄≥2岁的患有特定疾病的患者.
结论:
- 卢沃美替尼布在治疗罕见疾病方面取得了重大进展.
- 该药物为LCH和NF1患者提供了新的治疗选择.
- 此次批准标志着Fosun Pharma罕见病组合的关键里程碑.
相关概念视频
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K